Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Oncology /
      5. Bladder cancer

      Bladder cancer

      In Europe, over 224,000 people were diagnosed with bladder cancer in 2022 and there were more than 70,300 deaths.[1] At Johnson & Johnson we innovate with purpose to lead where medicine is going, striving to reduce this threat, helping patients and their loved ones find hope and relief.[2]

      To do this, we are developing targeted therapies and deepening our understanding of this complex disease, as we continue to focus on precision medicine and the enormous benefits it offers to patients, healthcare systems and society.[3]
      Bladder cancer, light micrograph
      Our understanding of bladder cancer
      In Europe, bladder cancer is the 5th most common cancer.[4]

      There is strong scientific evidence to show that the earlier the diagnosis of bladder cancer, the better the prognosis is for patients.[5]
      Bladder cancer in numbers
      • Bladder cancer incidence is approximately 4x more in men than in women.[6]

        Since the mid – to late 1990s, in many European nations incidence rates of bladder cancer have continued to rise, with the highest rate in Southern Europe, for both men and women.[7]

        Mortality rates in European men were by far the highest recorded worldwide, with the highest mortality in Western Europe.[8][9]
      • 9 out of 10 people are over the age of 55 when they are diagnosed.[10]

        Bladder cancer is the 5th most common cancer in Europe[11] and urothelial carcinoma is the most common type of bladder cancer.[12]
      • In 2022, there were approximately 224,000 new diagnoses of bladder cancer in Europe.[1]
      The power of targeted transformation

      We are focusing on better understanding the drivers of urothelial cancer, the most common type of bladder cancer and are exploring targeted therapies - alone and in combination - to transform outcomes.[12][13] This includes early intervention and optimising outcomes through locally-applied and targeted therapies, bladder-sparing regimens, and replacing Bacillus Calmette Guérin (BCG) as standard of care.[14][15] At Johnson & Johnson Oncology, average isn’t good enough. Our aim is to get in front of cancer, and we’re driven only to deliver the best outcomes to patients, partners, and the oncology community.

      Biomarker testing is the gatekeeper to enable the full potential of precision medicine.[3] We see enormous potential in the use of companion diagnostics, to ensure patients have access to the latest and most appropriate therapeutic opportunities.

      Recent research efforts in the field of precision oncology have provided key insights that have transformed the treatment paradigm, and will undoubtedly continue to expand our therapeutic options in the years to come.[16]

      We collaborate to innovate
      We fiercely believe cancer is a challenge we can collectively overcome, and our aim is to not only take down the disease, but to change and save lives. We know that change can only come through collaboration. Together with our partners, we leverage our expertise and scale and embrace external science in the pursuit of better outcomes for patients and their families, as we strive to deliver cures.
      Taris logo on white background
      Targeted releasing systems
      We’re very excited about the opportunity to advance the science of genitourinary cancers and improve the care of patients diagnosed with bladder cancer through our acquisition of TARIS Biomedical LLC in 2019.[18] The targeted releasing system is a drug delivery platform which has the potential to transform the delivery of active treatments locally for patients diagnosed with bladder cancer. The innovative silicone-based intravesical drug releasing system allows for the continuous release of medication directly to tumours.[19][20]

      We believe that the intravesical drug releasing system has the potential to be transformative in delivering active treatments locally with the ability to combine with systemic therapies to develop regimens for early stage non-muscle and muscle-invasive bladder cancer patients.[13][18]
      Collaborations
      As industry leaders, Johnson & Johnson Oncology is committed to ensuring success in our collaborations. Our Innovation and Business Development teams bring scientific, funding and commercial expertise to engage at all levels of research and development throughout the product lifecycle process.[17] Our flexible structure enables us to be agile and work effectively with a variety of partners to create the best business model for each collaboration.
      June 6, 2024
      More from oncology at Johnson & Johnson Innovative Medicine EMEA

      References

      [1] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table – bladder cancer incidence in 2022, both sexes, in Europe. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&sexes=0&group_populations=1&multiple_populations=1&populations=908&types=0. Accessed: April 2025.
      [2] Nature. Janssen Oncology—leading the way in transformational innovation. Available at: https://www.nature.com/articles/d43747-022-00205-3. Accessed: April 2025.
      [3] European Federation of Pharmaceutical Industries and Associations. Unlocking the potential of precision medicine in Europe. Policy recommendations February 2021. Available at: https://www.efpia.eu/media/589727/unlocking-the-potential-of-precision-medicine-in-europe.pdf. Accessed: April 2025.
      [4] European Cancer Patient Coalition. Bladder Cancer Awareness Month Campaign. Available at:  https://ecpc.org/get-involved/bladder-cancer-awareness-month-campaign/. Accessed: April 2025.
      [5] Cancer.org. Can Bladder Cancer Be Found Early? Available at: https://www.cancer.org/cancer/types/bladder-cancer/detection-diagnosis-staging/detection.html. Accessed: April 2025.
      [6] Cancer.net. Bladder Cancer: Statistics. Available at: https://www.cancer.net/cancer-types/bladder-cancer/statistics. Accessed: April 2025.
      [7] Saginala K, et al. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020 Mar 13;8(1):15. Doi: 10.3390/medsci8010015.
      [8] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table - bladder cancer mortality in 2022, both sexes, across continents. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=population&types=1&cancers=30. Accessed: April 2025.
      [9] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table – bladder cancer mortality in 2022, both sexes, in Europe. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=population&types=1&cancers=30&multiple_populations=1&populations=100_112_191_196_203_208_233_246_250_276_300_348_352_372_380_40_428_440_442_470_498_499_528_56_578_616_620_642_643_688_70_703_705_724_752_756_8_804_807_826. Accessed: April 2025.
      [10] American Cancer Society. Key Statistics for Bladder Cancer. Available at: https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html. Accessed: April 2025.
      [11] European Cancer Patient Coalition. Urological Cancer. Available at:  https://ecpc.org/news-events/bladder-cancer/. Accessed: April 2025.
      [12] Macmillan. Types of bladder cancer. Available at: https://www.macmillan.org.uk/cancer-information-and-support/bladder-cancer. Accessed: April 2025.
      [13] Clinicaltrials.gov. Janssen in urothelial carcinoma. Available at: https://clinicaltrials.gov/search?cond=erdafitinib%20OR%20tar-200%20OR%20ce&viewType=Table. Accessed: April 2025.
      [14] Montazeri K & Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020;13(1):1-6.
      [15] Soria F, et al. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. Curr Opin Urol. 2020. 30(4):542-546.
      [16] Liow E, Tran B. Precision oncology in urothelial cancer. ESMO Open 2020;5:e000616.
      [17] Johnson&Johnson Innovation.com. Available at: https://jnjinnovation.com/home. Accessed: April 2025.
      [18] Janssen. Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer. Available at: https://www.prnewswire.com/news-releases/johnson--johnson-acquires-taris-biomedical-with-focus-on-transforming-the-treatment-of-bladder-cancer-300978469.html. Accessed: April 2025.
      [19] Necchi A, et al. Results From SunRISe-1 in Patients (Pts) With Bacillus Calmette–Guérin (BCG)-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR NMIBC) Receiving TAR-200 Monotherapy. 2023 European Society for Medical Oncology Congress. October 22, 2023.
      [20] Vilaseca A, et al. First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). 2023 European Society for Medical Oncology Congress. October 22, 2023.

      CP-512004
      May 2025